Navigation Links
Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase
Date:4/12/2013

BOGOTA, Colombia, April 12, 2013 /PRNewswire/ -- Startup biotechnology company Neuralgene (http://neuralgene.com) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment of amyotrophic lateral sclerosis (ALS). PRCN-829 is the first gene therapy for sporadic ALS.

(Photo: http://photos.prnewswire.com/prnh/20130412/PH93428-a )

(Photo: http://photos.prnewswire.com/prnh/20130412/PH93428-b )

Neuralgene's neurotropic AAV-based gene therapy platform for the treatment of neurodegenerative diseases is based on the stem cell work performed by Jason Williams , M.D., founder and CEO of Neuralgene. "This technology addresses several key aspects of the underlying pathology of ALS," said Leonardo Gonzalez , M.D., clinical researcher for Neuralgene. "In his stem cell work, Dr. Williams had identified that production of Factor H by fat-derived mesenchymal stem cells may be a key mode of action."

The gene therapy is based on Dr. Williams' discovery that certain proteins produced by stem cells inhibit the attack of ALS. During the development of the gene therapy, he added new targets: neural growth factors and a protein implicated in ALS named TDP-43. "When Dr. Williams demonstrated the concept behind stem cells and how to address the treatment of ALS using gene therapy, we immediately knew that this was a revolutionary new concept," said Dr. Gonzalez.

The PRCN-829 gene therapy is designed to not only target gene delivery to the brain and spinal cord, but also to genetically engineer stem cells. The AAV9 viral vector delivers multiple genes, which include Factor H (a regulator of complement activity), neural growth
'/>"/>

SOURCE Neuralgene
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gene Therapy - Technologies, Markets and Companies
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Squamous Cell Cancer Responds to SPDT Therapy
6. Stem cell therapy reverses diabetes
7. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
8. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Safeguard Mezzanine Debt Facility; Support Profitable GrowthALISO VIEJO, Calif., ... (Nasdaq: CLRT ), a premier anatomic pathology ... the pharmaceutical industry, announced today that it has completed ... preferred stock with Oak Investment Partners ...
... May 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... American Society of Clinical Oncology (ASCO) Annual Meeting being ... related to our product candidates Stimuvax(R), PX-866 and PX-12 ... ASCO Web site, www.abstract.asco.org ., ...
... ATLANTA, May 18 /PRNewswire-Asia/ -- Global biomedical sciences ... the year 2008. This rides on,Singapore,s strong scientific ... in 2007. , The ... investment environment, as companies look to the fast ...
Cached Biology Technology:Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 2Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 3Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 4Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 5Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 6Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 4Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 5
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces it has ... for the 2015 International CES debut of the Wocket™ ... will be at the NXT-ID booth January 6th and 7 ...
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Physicists, chemists and engineers at the University of Pennsylvania ... of patchy particles, using charged, self-assembling molecules that may ... and perhaps be used in small batteries that store ... electrical charges of calcium ions just like the ...
... retinal prosthesis and fetal tissue transplant, restored some vision ... at Neuroscience 2009, the annual meeting of the Society ... news on brain science and health, may lead to ... an engineered protein restored vision in an animal model ...
... researchers from the United States, Korea, and France has sequenced ... E. coli bacteria, one used to study evolution ... practical applications. The findings will help guide future research and ... classical research that is the foundation of our understanding of ...
Cached Biology News:Penn team uses self-assembly to make molecule-sized particles with patches of charge 2Experimental treatments restore partial vision to blind people 2Genomes of 2 popular research strains of E. coli sequenced 2Genomes of 2 popular research strains of E. coli sequenced 3
... FLUOstar OPTIMA is a fully automated ... life science labs in academia and ... measurement principles: Fluorescence Intensity ... Time-Resolved Fluorescence including DELFIATM ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... Security ChemStation is a ... application for data acquisition, ... searching and reporting, addressing ... data security, integrity, and ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known mammal microRNAs ...
Biology Products: